US20020013373A1 - Methods and compositions for treatment of asthma - Google Patents
Methods and compositions for treatment of asthma Download PDFInfo
- Publication number
- US20020013373A1 US20020013373A1 US09/770,631 US77063101A US2002013373A1 US 20020013373 A1 US20020013373 A1 US 20020013373A1 US 77063101 A US77063101 A US 77063101A US 2002013373 A1 US2002013373 A1 US 2002013373A1
- Authority
- US
- United States
- Prior art keywords
- propranolol
- asthma
- sheep
- treatment
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000006673 asthma Diseases 0.000 title claims abstract description 72
- 239000000203 mixture Substances 0.000 title claims abstract description 61
- 238000011282 treatment Methods 0.000 title claims abstract description 35
- 238000000034 method Methods 0.000 title claims abstract description 34
- 241001465754 Metazoa Species 0.000 claims abstract description 17
- AQHHHDLHHXJYJD-CQSZACIVSA-N (R)-(+)-propranolol Chemical compound C1=CC=C2C(OC[C@H](O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-CQSZACIVSA-N 0.000 claims description 59
- 239000000039 congener Substances 0.000 claims description 12
- 239000002207 metabolite Substances 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 206010061218 Inflammation Diseases 0.000 claims description 7
- 230000004054 inflammatory process Effects 0.000 claims description 7
- 229960002781 bisoprolol Drugs 0.000 claims description 6
- VHYCDWMUTMEGQY-UHFFFAOYSA-N bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 claims description 6
- 229960004195 carvedilol Drugs 0.000 claims description 6
- NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 claims description 6
- 229960002237 metoprolol Drugs 0.000 claims description 6
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000010083 bronchial hyperresponsiveness Effects 0.000 claims 1
- 230000007170 pathology Effects 0.000 abstract description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 230000028709 inflammatory response Effects 0.000 abstract description 5
- 241001494479 Pecora Species 0.000 description 50
- 230000004044 response Effects 0.000 description 37
- 239000000427 antigen Substances 0.000 description 36
- 102000036639 antigens Human genes 0.000 description 33
- 108091007433 antigens Proteins 0.000 description 33
- 230000000694 effects Effects 0.000 description 30
- 150000001875 compounds Chemical class 0.000 description 29
- 238000009472 formulation Methods 0.000 description 25
- AQHHHDLHHXJYJD-AWEZNQCLSA-N (2s)-1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-ol Chemical compound C1=CC=C2C(OC[C@@H](O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-AWEZNQCLSA-N 0.000 description 18
- 230000001154 acute effect Effects 0.000 description 16
- 210000004072 lung Anatomy 0.000 description 15
- 230000010085 airway hyperresponsiveness Effects 0.000 description 13
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 description 12
- 239000004480 active ingredient Substances 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 230000009977 dual effect Effects 0.000 description 12
- 239000007788 liquid Substances 0.000 description 11
- 239000000843 powder Substances 0.000 description 11
- 230000003078 antioxidant effect Effects 0.000 description 9
- 230000008859 change Effects 0.000 description 9
- 230000004043 responsiveness Effects 0.000 description 9
- 206010006482 Bronchospasm Diseases 0.000 description 8
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 8
- 239000000443 aerosol Substances 0.000 description 8
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 230000000638 stimulation Effects 0.000 description 8
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 8
- 229960004484 carbachol Drugs 0.000 description 7
- 210000003630 histaminocyte Anatomy 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 241000244188 Ascaris suum Species 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 239000000048 adrenergic agonist Substances 0.000 description 5
- 230000000172 allergic effect Effects 0.000 description 5
- 208000010668 atopic eczema Diseases 0.000 description 5
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 5
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 5
- 230000007885 bronchoconstriction Effects 0.000 description 5
- 229960000265 cromoglicic acid Drugs 0.000 description 5
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 108700025647 major vault Proteins 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 206010066091 Bronchial Hyperreactivity Diseases 0.000 description 4
- 108010028275 Leukocyte Elastase Proteins 0.000 description 4
- 102000016799 Leukocyte elastase Human genes 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 230000036427 bronchial hyperreactivity Effects 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 229960001340 histamine Drugs 0.000 description 4
- 230000004047 hyperresponsiveness Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 210000000440 neutrophil Anatomy 0.000 description 4
- 230000001590 oxidative effect Effects 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 229960000278 theophylline Drugs 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- 208000009079 Bronchial Spasm Diseases 0.000 description 3
- 208000014181 Bronchial disease Diseases 0.000 description 3
- 201000003883 Cystic fibrosis Diseases 0.000 description 3
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 3
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 208000037883 airway inflammation Diseases 0.000 description 3
- 239000013566 allergen Substances 0.000 description 3
- 239000002876 beta blocker Substances 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 229960001334 corticosteroids Drugs 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 3
- 239000003380 propellant Substances 0.000 description 3
- 150000003180 prostaglandins Chemical class 0.000 description 3
- 235000019833 protease Nutrition 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000000115 thoracic cavity Anatomy 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 description 2
- 241000220479 Acacia Species 0.000 description 2
- 208000000884 Airway Obstruction Diseases 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 230000036428 airway hyperreactivity Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 229940097320 beta blocking agent Drugs 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000000621 bronchi Anatomy 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 229960003712 propranolol Drugs 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 230000008728 vascular permeability Effects 0.000 description 2
- 238000009423 ventilation Methods 0.000 description 2
- RTAPDZBZLSXHQQ-UHFFFAOYSA-N 8-methyl-3,7-dihydropurine-2,6-dione Chemical class N1C(=O)NC(=O)C2=C1N=C(C)N2 RTAPDZBZLSXHQQ-UHFFFAOYSA-N 0.000 description 1
- 206010001382 Adrenal suppression Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- RINPLGHRMWRINE-UHFFFAOYSA-N C.CC(C)NCC(O)COc1cccc2ccccc12.CCOCCOCc1ccc(OCC(O)CNC(C)C)cc1.COCCc1ccc(OCC(O)CNC(C)C)cc1.COc1ccccc1OCCNCC(O)COc1cccc2c1-c1ccccc1N2 Chemical compound C.CC(C)NCC(O)COc1cccc2ccccc12.CCOCCOCc1ccc(OCC(O)CNC(C)C)cc1.COCCc1ccc(OCC(O)CNC(C)C)cc1.COc1ccccc1OCCNCC(O)COc1cccc2c1-c1ccccc1N2 RINPLGHRMWRINE-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 241000777300 Congiopodidae Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 108090000235 Myeloperoxidases Proteins 0.000 description 1
- 102000003896 Myeloperoxidases Human genes 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- 206010073310 Occupational exposures Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000003826 Respiratory Acidosis Diseases 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 239000000464 adrenergic agent Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000004479 aerosol dispenser Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940030611 beta-adrenergic blocking agent Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 239000004044 bronchoconstricting agent Substances 0.000 description 1
- 230000003435 bronchoconstrictive effect Effects 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 238000002663 nebulization Methods 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 231100000675 occupational exposure Toxicity 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940124624 oral corticosteroid Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000004648 relaxation of smooth muscle Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 229940124629 β-receptor antagonist Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
Definitions
- the present invention relates to methods and compositions for the treatment of pathologies associated with asthma and inflammatory responses in a human or animal.
- the present invention comprises compositions and methods for the treatment of asthma by administration of pharmaceutical preparations including D-propranolol.
- Asthma is a lung disease characterized by a usually reversible airway obstruction, airway inflammation and increased airway responsiveness to stimuli.
- the airway obstruction in an asthma attack is thought to be due to the combination of bronchospasm of the smooth muscles of the bronchial tree, increased mucous section, edema of airway mucosa due to increased vascular permeability, cellular infiltration of the airway walls, and injury to airway epithelium.
- Asthma may be triggered by a variety of causes such as allergic reactions, a secondary response to infections, industrial or occupational exposures, ingestion of certain chemicals or drugs, exercise, and vasculitis. Regardless of the trigger, many of the pathological features of asthma can be attributed to mast cell degranulation. Mast cells will degranulate in response to many conditions in addition to the classical IgE-antigen stimulation. Not wishing to be bound by the following theory, it is theorized that when the asthmatic, human or animal, inhales an allergenic substance, sensitized IgE antibodies trigger mast cell degranulation in the lung interstitium.
- the mast cell degranulation releases among other factors, histamine, bradykinin, and slow-reacting substance of anaphylaxis (SRS-A) which includes the leukotrienes C, D and E, prostaglandins including PGF 2 , PGF 2 ⁇ , and PGD 2 , and thromboxane A 2 .
- SRS-A anaphylaxis
- the histamine then attaches to receptor sites in the larger bronchi, causing irritation, inflammation and edema.
- the SRS-A attaches to receptor sites in the smaller bronchi, causing edema and attracting prostaglandins, which enhance the effects of histamine in the lungs.
- histamine also stimulates excessive mucous secretion, further narrowing the bronchial lumen.
- the narrowed bronchial lumen still expands slightly, allowing air to reach the alveoli.
- the increased thoracic pressure closes the bronchial lumen completely.
- air can enter, but not exit the lungs.
- Mucous then fills the lung bases, inhibiting alveolar ventilation.
- blood is shunted to other alveoli. Without adequate compensation, hypoxia, and in extreme cases, respiratory acidosis may result.
- the early phase includes the immediate inflammatory response including the reactions caused by the release of cellular mediators from mast cells.
- Late phase reactions develop over a period of hours and are characterized histologically by an early influx of polymorphonuclear leukocytes and fibrin deposition followed later by infiltration of eosinophils. Late phase reactions increase airway reactivity and lead to prolonged asthmatic exacerbations that may last from hours to days to months in some subjects.
- One of the residual effects of asthma reactions is this hyperresponsiveness of the airways to nonspecific stimuli.
- adrenergic agonists mimic the physiological effects of the adrenal medullary hormones and neurotransmitters of the sympathetic nervous system.
- the ideal therapeutic target for asthma would be a compound that affected the ⁇ 2 -receptors in the lung. ⁇ 2 -receptors are found in the airway and their stimulation causes smooth muscle relaxation, increased chloride fluxes and reduced vascular permeability. These effects would be very useful in asthma therapy.
- adrenergic agonists are generally not selective for only the ⁇ 2 -receptors, but also effect the ⁇ -receptors and ⁇ 1 -receptors.
- ⁇ 1 -receptors are found in the heart and adrenergic stimulation also leads to cardiac stimulation, which is a serious side effect of treatment with adrenergic agonists.
- many of these compounds are rapidly metabolized and have very short half-lives, and thus are not effective therapy for asthma or hyperresponsiveness reactions.
- ⁇ 2 -adrenergic agonists can be used for treatment of bronchospasm, but have no effect on airway inflammation or bronchial hyperreactivity.
- Asthma may also be treated with methylxanthines, such as theophylline.
- methylxanthines such as theophylline.
- the side effects of theophylline are nervousness, nausea, vomiting, anorexia, abdominal discomfort and headache. It is difficult to reach an effective drug level that provides asthma control without triggering side effects.
- Corticosteroids are used to treat asthma by reducing the inflammatory component. Because the late-phase asthmatic response is poorly responsive to bronchodilators, corticosteroids are used to treat late-phase and airway hyperreactivity reactions. These agents have tremendous toxicity in children, including adrenal suppression and reduced bone density and growth. In all age groups, corticosteroids have numerous side effects and complications which impact major organ systems. Use of oral corticosteroids must be closely monitored and its use curtailed or halted as soon as possible.
- Cromolyn another well known asthma therapeutic, acts by stabilizing mast cells and reducing or preventing release of the cellular mediators.
- cromolyn is effective in stopping or reducing both the early and late phases of asthma inflammatory reactions.
- Cromolyn is only effective in preventing the onset of an asthma reaction if given prior to an asthma attack. Once the asthma reaction has begun, the mediators have been released and treatment with cromolyn would do nothing to relieve the bronchoconstriction and hyperresponsiveness. Thus, asthma patients would have to take cromolyn continuously to prevent future asthma attacks that may or may not occur.
- compositions and methods are provided that are effective in preventing asthma and related pathologies. These methods and compositions are effective against inflammatory reactions in humans or animals. These compositions are easily administered by an oral route and can be given in dosages that are safe and effective.
- the present invention provides a method of treating asthma and related pathologies by administering a composition comprising a compound with anti-oxidant properties in a dosage sufficient to inhibit asthma.
- compositions and methods to inhibit asthma and related pathologies in a human or animal are provided.
- Still another object of the present invention is to provide methods and compositions that are effective in diminishing specific and non-specific bronchial hyperreactivity.
- FIG. 1 is a graph showing the effect of D-propranolol in acute responder allergic sheep. Data are shown as mean ⁇ SE specific lung resistance (SR L ), for the baseline, after D-propranolol (PD) and for up to two hours post-antigen. D-propranolol was administered one hour before the antigen challenge (10 mg in 4 mL of PBS). Significantly different from antigen control (P ⁇ 0.05).
- FIG. 3 is a graph showing the individual response of each sheep as percentage change in specific lung resistance (SR L ) after pretreatment with D-propranolol.
- FIG. 4 is a graph showing the effect of pretreatment with inhaled D-propranolol (10 mg in 4 mL of PBS) on antigen-induced airway hyperresponsiveness. Data are shown as mean ⁇ SE PD 400 of carbachol in breath units (Cumulative provocating dose of carbachol, which increased SR L to 400% above the baseline). One breath unit is defined as one breath of 1% carbachol solution (P ⁇ NS).
- FIG. 5 is a graph showing the individual response of each sheep to the effect of pretreatment with inhaled D-propranolol on antigen-induced changes in PD 400 .
- FIG. 6 is a graph showing the SR L response of acute responder sheep to different dosages of inhaled D-propranolol. The response at the 10 mg/kg dose is significantly different from the control.
- FIG. 7 is a graph showing the PD 400 response of acute responder sheep to different dosages of inhaled D-propranolol.
- the post antigen and 5 mg dose responses are significantly different from the baseline response, and the 20 mg dose response is significantly different from the post antigen response.
- FIG. 8 is a graph showing the SR L response of acute responder sheep to a 10 mg dose of inhaled L-propranolol. There is no significant difference from the control response.
- FIG. 9 is a graph showing the PD 400 response of acute responder sheep to a 10 mg dose of inhaled L-propranolol.
- FIG. 10 is a graph showing the SR L response of acute responder sheep to a 5 mg/kg dose of oral D-propranolol.
- FIG. 11 is a graph showing the PD 400 response of acute responder sheep to a 5 mg/kg dose of oral D-propranolol.
- FIG. 12 is a chart showing the timeline of the SR L response of dual responder sheep to a 5 mg/kg dose of inhaled D-propranolol.
- FIG. 13 is a graph showing the PD 400 response of dual responder sheep to a 5 mg/kg dose of inhaled D-propranolol.
- FIG. 14 is a chart showing the timeline of the SR L response of dual responder sheep to a 10 mg/kg dose of inhaled D-propranolol.
- FIG. 15 is a graph showing the PD 400 response of dual responder sheep to a 10 mg/kg dose of inhaled D-propranolol.
- FIG. 16 is a chart showing the timeline of the SR L response of dual responder sheep to a 5 mg/kg dose of oral D-propranolol.
- FIG. 17 is a graph showing the PD 400 response of dual responder sheep to a 5 mg/kg dose of oral D-propranolol.
- FIG. 18 is a chart showing the timeline of the SR L response of dual responder sheep to a 10 mg/kg dose of inhaled L-propranolol.
- FIG. 19 is a graph showing the PD 400 response of dual responder sheep to a 10 mg/kg dose of inhaled L-propranolol.
- the present invention includes compositions and methods for the treatment of asthma and related pathologies.
- the present invention also includes compounds that may have antioxidant activity and in some cases, lack ability to block beta receptors in the human or animal.
- the present invention comprises methods of treating asthma in a human or animal comprising the steps of administering to the human or animal with the asthma a composition comprising an effective amount of an antioxidant compound.
- One embodiment of the present invention is the use of D-propranolol or the congeners of D-propranolol as disclosed herein to inhibit asthma and related pathologies.
- the optical isomer of D-propranolol is L-propranolol.
- L-propranolol is in the class of drugs that cause beta receptor blockade.
- ⁇ -adrenergic blocking agents have been used to treat such diverse diseases as glaucoma, migraine. hypertension, myocardial infarct and tremor.
- L-propranolol is administered orally and is metabolically converted in the body by hepatic p450 enzymes to a metabolite that is effective for blocking beta receptors found in bodily tissues such as the heart and lung, in addition to other organs.
- L-propranolol is used to treat high blood pressure and certain forms of angina.
- L-propranolol's sympathetic agonist or beta-blocker activity makes it an effective therapeutic for cardiac and hypertensive conditions, but this same activity creates adverse reactions for asthmatics.
- L-propranolol can precipitate asthma and in patients with severe asthma, the use of L-propranolol is contraindicated because serious or lethal asthmatic episodes of bronchoconstriction can occur.
- D-propranolol is thought to be biologically inactive.
- D-propranolol is effective therapy for asthma.
- D-propranolol is effective in the prevention of antigen-induced bronchoconstriction in sheep.
- the sheep model is a good animal model for the asthmatic condition in humans.
- D-propranolol, its metabolites and congeners and analogs play a role in stopping or inhibiting the inflammatory reactions mediated by mast cells and other inflammatory agents in asthma.
- Control of inflammatory reactions by D-propranolol, its metabolites and congeners and analogs make such compounds useful for treatment of other pathologies with inflammatory components.
- Diseases associated with chronic inflammation can be treated by the compositions and methods of the present invention.
- Diseases with symptoms of chronic inflammation include, but are not limited to, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, psoriasis, sarcoidosis and rheumatoid arthritis.
- the antioxidant activities of the compositions of the present invention aid in the compositions' effectiveness in treatment of asthma.
- An antioxidant is more readily oxidized than is a second substance and therefore, the antioxidant retards or inhibits the oxidation of the second substance.
- Treatment of other disease states in which control of oxidative activity is relevant is contemplated by the methods and compositions of the present invention.
- Cystic fibrosis is a genetic disease in which there is, among other pathologies, an overproduction of a thickened mucous and lack of digestive enzymes.
- Neutrophil elastase released during an inflammatory response, is thought to play a central role in cystic fibrosis and in inflammatory disorders.
- Neutrophil elastase is a serine protease that is stored in granules of mature neutrophils and functions in degradation of phagocytosed proteins. During neutrophil stimulation, neutrophil elastase and other enzymes gain access to the extracellular space where they cause substantial damage to the surrounding lung tissue, inhibit cell functions and inactivate molecules relevant to the integrity of the lung.
- the lung is protected from neutrophil elastase and other such enzymes by several antiproteinases such as ⁇ 1 -proteinase inhibitor ( ⁇ 1 -PI) and secretory leucoprotease inhibitor (SLPI).
- ⁇ 1 -PI ⁇ 1 -proteinase inhibitor
- SLPI secretory leucoprotease inhibitor
- compositions and methods of the present invention can be used to treat asthmatic animals such as race horses. Additionally, animals also suffer with diseases due to inflammatory and oxidative reactions.
- Compounds that can be used in accordance with the present invention include compounds that lack beta blocker activity. Additionally, compounds that can be used in accordance with the present invention include compounds that are capable of being acted on by the class of enzymes identified as p450 enzymes.
- Examples of compounds included in the present invention comprise D-propranolol and its congeners, including fluorinated congeners and analogs. Additional examples include the appropriate optical isomer of carvedilol, metoprolol, bisoprolol and their metabolites and congeners and analogs.
- a preferred compound is D-propranolol as well as congeners, analogs, hydrolysis products, metabolites and precursors of D-propranolol and may lack beta receptor blocking capabilities. Such compounds may also have antioxidative activity.
- Other preferred compounds are the appropriate enantimers or racemic mixture of bisoprolol, metoprolol, and carvedilol. It is envisioned that fluorinated congeners of all of these compounds are also useful for the present invention. However, it is to be understood that it is not necessary for a compound to have both a lack of beta receptor blocking activity and antioxidative activity to be considered part of the present invention. Such compounds as those acted upon by p450 enzymes are also contemplated by the present invention. It is to be understood that the compounds of the present invention can exist as enantiomers and that the racemic mixture of enantiomers or the isolated enantiomers are all considered as within the scope of the present invention.
- the compounds described above can be provided as pharmaceutically acceptable formulations using formulation methods known to those of ordinary skill in the art. These formulations can be administered by standard routes. In general, the combinations may be administered by the topical, transdermal, oral, nasal, rectal or parenteral (e.g., intravenous, subcutaneous or intramuscular) route. In addition, the combinations may be incorporated into biodegradable polymers allowing for sustained release of the compound.
- the compounds of the present invention may be delivered via any inhalation methods known to those skilled in the art.
- inhalation methods and devices include, but are not limited to, metered dose inhalers with propellants such as CFC or HFA or propellants that are physiologically and environmentally acceptable.
- propellants such as CFC or HFA
- Other included devices are breath operated inhalers, multidose dry powder inhalers and aerosol nebulizers.
- the dosage of the compound will depend on the condition being treated, the particular compound, and other clinical factors such as weight and condition of the human or animal and the route of administration of the compound. It is to be understood that the present invention has application for both human and veterinary use.
- the formulations include those suitable for oral, inhalation, rectal, ophthalmic, (including intravitreal or intracameral) nasal, topical (including buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intratracheal, and epidural) administration.
- the formulations may conveniently be presented in unit dosage form and may be prepared by conventional pharmaceutical techniques. Such techniques include the step of bringing into association the active ingredient and the pharmaceutical carrier(s) or excipient(s). In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.
- Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil emulsion and as a bolus, etc.
- a tablet may be made by compression or molding, optionally with one or more accessory ingredients.
- Compressed tablets may be prepared by compressing, in a suitable machine, the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, preservative, surface active or dispersing agent.
- Molded tablets may be made by molding, in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent.
- the tablets may be optionally coated or scored and may be formulated so as to provide a slow or controlled release of the active ingredient therein.
- Formulation suitable for administration by inhalation includes formulations of the active ingredient in a form that can be dispensed by such inhalation devices known to those in the art. Such formulations may includes carriers such as powders and aerosols.
- the inhalant compositions used in the present invention may comprise liquid or powdered compositions containing the active ingredient that are suitable for nebulization and intrabronchial use, or aerosol compositions administered via an aerosol unit dispensing metered doses.
- Suitable liquid compositions comprise the active ingredient in an aqueous, pharmaceutically acceptable inhalant solvent, e.g., isotonic saline or bacteriostatic water.
- the solutions are administered by means of a pump or squeeze-actuated nebulized spray dispenser, or by any other conventional means for causing or enabling the requisite dosage amount of the liquid composition to be inhaled into the patient's lungs.
- Suitable powder compositions include, by way of illustration, powdered preparations of the active ingredient thoroughly intermixed with lactose or other inert powders acceptable for intrabronchial administration.
- the powder compositions can be administered via an aerosol dispenser or encased in a breakable capsule which may be inserted by the patient into a device that punctures the capsule and blows the powder out in a steady stream suitable for inhalation.
- Aerosol formulations for use in the subject method would typically include propellants, surfactants and co-solvents and may be filled into conventional aerosol containers that are closed by a suitable metering valve.
- Formulations suitable for topical administration in the mouth include lozenges comprising the ingredients in a flavored basis, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert basis such as gelatin and glycerin, or sucrose and acacia; and mouthwashes comprising the ingredient to be administered in a suitable liquid carrier.
- Formulations suitable for topical administration to the skin may be presented as ointments, creams, gels and pastes comprising the ingredient to be administered in a pharmaceutical acceptable carrier.
- a preferred topical delivery system is a transdermal patch containing the ingredient to be administered.
- Formulations for rectal administration may be prepared as a suppository with a suitable base comprising, for example, cocoa butter or a salicylate.
- Formulations suitable for nasal administration include a coarse powder having a particle size, for example, in the range of 20 to 500 microns which is administered in the manner in which snuff is administered, i.e., by rapid inhalation through the nasal passage from a container of the powder held close up to the nose.
- Suitable formulations, wherein the carrier is a liquid, for administration, as for example, a nasal spray or as nasal drops, include aqueous or oily solutions of the active ingredient.
- Formulations suitable for vaginal administration may be presented as pessaries, tamports, creams, gels, pastes, foams or spray formulations containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
- Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain antioxidants, stabilizers, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.
- the formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) conditions requiring only the addition of the sterile liquid carrier, for example, water for injections, immediately prior to use.
- Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
- Preferred unit dosage formulations are those containing a daily dose or unit, daily sub-dose, as herein above recited, or an appropriate fraction thereof, of the administered ingredient.
- formulations of the present invention may include other agents conventional in the art having regard to the type of formulation in question, for example, those suitable for oral administration may include flavoring agents.
- D-propranolol was administered via the inhalation route as an aerosol one hour before antigen challenge in acute responder sheep. There was significant inhibition of allergic bronchoconstriction by the administered D-propranolol.
- FIG. 1 shows the effect of treatment using D-propranolol in an antigen challenge experiment.
- the normal reaction of the sheep to the antigen from Ascaris suum is measured. After full recovery and a two week rest period, the sheep again undergo repeat antigen challenge, but this time only after treatment with D-propranolol.
- the SR L of the acute responder sheep was measured prior to any treatment (baseline).
- the normal response of the sheep to antigen challenge by Ascaris suum antigen was measured (Open circles).
- D-propranolol 10 mg in 4 mL of PBS, (phosphate buffered saline)
- PBS phosphate buffered saline
- PD phosphate buffered saline
- the SR L was measured immediately after antigen challenge (AG 0 ).
- the sheep treated with D-propranolol black circles
- FIG. 2 shows the percentage change in SR L for control conditions (normal response to Ascaris suum antigen) and treatment conditions (D-propranolol).
- control conditions normal response to Ascaris suum antigen
- treatment conditions D-propranolol
- FIG. 3 shows the individual responses for the five sheep. As the graph shows, there was variability in the responses of the five sheep, but all sheep showed a difference in response to antigen after treatment with D-propranolol.
- FIG. 4 shows that treatment with D-propranolol maintains the sheep's airway responsiveness to antigen at or near baseline responsiveness levels. The effect of antigen on the sheep was to make the airway more responsive, thus lowering the PD 400 value. Treatment with D-propranolol maintained the airway responsiveness levels at the baseline or normal responsiveness levels of the sheep.
- FIG. 5 shows the individual airway responsiveness of each sheep to the treatment with D-propranolol. When challenged by antigen, each sheep showed a decreased PD 400 . The effect of treatment with D-propranolol on airway responsiveness was different for each sheep.
- SR L Specific lung resistance
- AHR was inhibited by 30 % at a 5 mg dose, 50% at a 10 mg dose, and 75% at a 20 mg dose.
- the 75% inhibition is significant, P ⁇ 0.05, when compared to the post-antigen response.
- the 5 mg dose response is significantly different from the baseline response.
- FIG. 9 shows the AHR response to inhaled L-propranolol where there is no difference between the post antigen and L-propranolol responses, though both are statistically different from the baseline response.
- FIG. 10 shows the change in SR L to a 5 mg/kg dose of oral D-propranolol in acute responder sheep and
- FIG. 11 shows the change in PD 400 after oral administration of 5 mg/kg of D-propranolol.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention comprises methods and compositions for the treatment of bronchorestrictive disorders, including asthma, in humans or animals. The methods and compositions are effective in treatment of inflammatory responses, such as those found in asthma and other related pathologies.
Description
- This application claims priority to U.S. Provisional Application No. 60/040,745, filed Mar. 13, 1997.
- The present invention relates to methods and compositions for the treatment of pathologies associated with asthma and inflammatory responses in a human or animal. In particular, the present invention comprises compositions and methods for the treatment of asthma by administration of pharmaceutical preparations including D-propranolol.
- More than ten million persons in the United States suffer from asthma and related inflammatory lung diseases. The numbers of persons with asthma is increasing both in the United States and worldwide. The morbidity associated with asthma makes asthma a major medical condition. Asthma is the most common chronic disease of childhood and the leading cause among chronic illnesses of school absences. Asthma in humans results in an estimated 27 million patient visits, 6 million lost workdays, and 90.5 million days of restricted activity per year. In addition to its morbidity, the mortality rate for asthma is growing worldwide. Additionally, asthma reactions are a growing problem for animals. In particular, the horse racing industry is affected by horses that suffer from asthmatic reactions.
- Asthma is a lung disease characterized by a usually reversible airway obstruction, airway inflammation and increased airway responsiveness to stimuli. The airway obstruction in an asthma attack is thought to be due to the combination of bronchospasm of the smooth muscles of the bronchial tree, increased mucous section, edema of airway mucosa due to increased vascular permeability, cellular infiltration of the airway walls, and injury to airway epithelium.
- Asthma may be triggered by a variety of causes such as allergic reactions, a secondary response to infections, industrial or occupational exposures, ingestion of certain chemicals or drugs, exercise, and vasculitis. Regardless of the trigger, many of the pathological features of asthma can be attributed to mast cell degranulation. Mast cells will degranulate in response to many conditions in addition to the classical IgE-antigen stimulation. Not wishing to be bound by the following theory, it is theorized that when the asthmatic, human or animal, inhales an allergenic substance, sensitized IgE antibodies trigger mast cell degranulation in the lung interstitium. The mast cell degranulation releases among other factors, histamine, bradykinin, and slow-reacting substance of anaphylaxis (SRS-A) which includes the leukotrienes C, D and E, prostaglandins including PGF2, PGF2α, and PGD2, and thromboxane A2. The histamine then attaches to receptor sites in the larger bronchi, causing irritation, inflammation and edema. The SRS-A attaches to receptor sites in the smaller bronchi, causing edema and attracting prostaglandins, which enhance the effects of histamine in the lungs. With the help of the prostaglandins, histamine also stimulates excessive mucous secretion, further narrowing the bronchial lumen. When the asthmatic inhales, the narrowed bronchial lumen still expands slightly, allowing air to reach the alveoli. However, upon exertion to exhale, the increased thoracic pressure closes the bronchial lumen completely. Thus, in an asthma attack, air can enter, but not exit the lungs. Mucous then fills the lung bases, inhibiting alveolar ventilation. In an effort to compensate for lowered alveolar ventilation, blood is shunted to other alveoli. Without adequate compensation, hypoxia, and in extreme cases, respiratory acidosis may result.
- In many cases, there are two phases to an allergic asthma attack, an early phase and a late phase which follows 4-6 hours after bronchial stimulation. The early phase includes the immediate inflammatory response including the reactions caused by the release of cellular mediators from mast cells. Late phase reactions develop over a period of hours and are characterized histologically by an early influx of polymorphonuclear leukocytes and fibrin deposition followed later by infiltration of eosinophils. Late phase reactions increase airway reactivity and lead to prolonged asthmatic exacerbations that may last from hours to days to months in some subjects. One of the residual effects of asthma reactions is this hyperresponsiveness of the airways to nonspecific stimuli.
- The current treatments for asthma are not adequate and many have serious side effects. The general goals of drug therapy for asthma are prevention of bronchospasm and control of airway hyperreactivity or hyperresponsiveness, an indication of airway inflammation. One effective treatment is avoidance of all allergens that trigger an asthma attack. Though scrupulous housecleaning and air cleansing devices can lessen the exposures to allergens, it is very difficult to eliminate all exposures to allergens. Thus, most asthmatics are treated with pharmacological agents that have side effects.
- Another common treatment regimen is administration of adrenergic agonists. These compounds mimic the physiological effects of the adrenal medullary hormones and neurotransmitters of the sympathetic nervous system. The ideal therapeutic target for asthma would be a compound that affected the β2-receptors in the lung. β2-receptors are found in the airway and their stimulation causes smooth muscle relaxation, increased chloride fluxes and reduced vascular permeability. These effects would be very useful in asthma therapy.
- Many side effects result from treatment with adrenergic agonists because the adrenergic agonists are generally not selective for only the β2-receptors, but also effect the α-receptors and β1-receptors. β1-receptors are found in the heart and adrenergic stimulation also leads to cardiac stimulation, which is a serious side effect of treatment with adrenergic agonists. Additionally, many of these compounds are rapidly metabolized and have very short half-lives, and thus are not effective therapy for asthma or hyperresponsiveness reactions. β2-adrenergic agonists can be used for treatment of bronchospasm, but have no effect on airway inflammation or bronchial hyperreactivity. In fact, chronic use of β2-adrenergic agents alone, by down regulation of β2-receptors, may worsen bronchial hyperreactivity.
- Asthma may also be treated with methylxanthines, such as theophylline. There is substantial variability in the absorbance and clearance of theophylline among animals. Even in individuals, theophylline clearance is effected by many physiological situations such as infection, antibiotic use, cigarette use and diet. The side effects of theophylline are nervousness, nausea, vomiting, anorexia, abdominal discomfort and headache. It is difficult to reach an effective drug level that provides asthma control without triggering side effects.
- Corticosteroids are used to treat asthma by reducing the inflammatory component. Because the late-phase asthmatic response is poorly responsive to bronchodilators, corticosteroids are used to treat late-phase and airway hyperreactivity reactions. These agents have tremendous toxicity in children, including adrenal suppression and reduced bone density and growth. In all age groups, corticosteroids have numerous side effects and complications which impact major organ systems. Use of oral corticosteroids must be closely monitored and its use curtailed or halted as soon as possible.
- Cromolyn, another well known asthma therapeutic, acts by stabilizing mast cells and reducing or preventing release of the cellular mediators. Thus, cromolyn is effective in stopping or reducing both the early and late phases of asthma inflammatory reactions. Cromolyn is only effective in preventing the onset of an asthma reaction if given prior to an asthma attack. Once the asthma reaction has begun, the mediators have been released and treatment with cromolyn would do nothing to relieve the bronchoconstriction and hyperresponsiveness. Thus, asthma patients would have to take cromolyn continuously to prevent future asthma attacks that may or may not occur.
- Thus, there is a long felt need for methods and compositions that are capable of inhibiting and stopping an asthma attack and its associated conditions, which are easily administered, and which do not have the side effects of currently used therapies. A simple and efficacious method of treatment would be through the inhalation route. If an anti-asthma agent could be given by an oral route, the many aspects of the pathology discussed above could be treated easily. The optimal dosage could be distributed in a form that the patient could self-administer at the onset of an attack or to stop hyperresponsiveness of the airways.
- In accordance with the present invention, compositions and methods are provided that are effective in preventing asthma and related pathologies. These methods and compositions are effective against inflammatory reactions in humans or animals. These compositions are easily administered by an oral route and can be given in dosages that are safe and effective. The present invention provides a method of treating asthma and related pathologies by administering a composition comprising a compound with anti-oxidant properties in a dosage sufficient to inhibit asthma.
- Accordingly, it is an object of the present invention to provide compositions and methods to inhibit asthma and related pathologies in a human or animal.
- It is yet another object of the present invention to provide a composition of inhibiting asthma and related pathologies by oral or inhaled administration of the composition.
- It is another object of the present invention to provide methods for treatment for asthma.
- It is another object of the present invention to provide methods for treatment for pathologies mediated by asthma.
- It is yet another object of the present invention to provide a treatment for inflammatory responses.
- It is an object of the present invention to provide methods and compositions for treatment of antigen-induced asthma.
- It is an object of the present invention to provide methods and compositions for treatment of bronchial hyperreactivity.
- Still another object of the present invention is to provide methods and compositions that are effective in diminishing specific and non-specific bronchial hyperreactivity.
- These and other objects, features and advantages of the present invention will become apparent after a review of the following detailed description of the disclosed embodiments and the appended claims.
- FIG. 1 is a graph showing the effect of D-propranolol in acute responder allergic sheep. Data are shown as mean ± SE specific lung resistance (SRL), for the baseline, after D-propranolol (PD) and for up to two hours post-antigen. D-propranolol was administered one hour before the antigen challenge (10 mg in 4 mL of PBS). Significantly different from antigen control (P<0.05).
- FIG. 2 is a graph showing the percentage of change in specific lung resistance (SRL) in acute responder sheep after pretreatment with D-propranolol. Data shown are mean ± SE % change in specific lung resistance (SRL) (n=5). Significantly different from antigen control (P<0.05).
- FIG. 3 is a graph showing the individual response of each sheep as percentage change in specific lung resistance (SRL) after pretreatment with D-propranolol.
- FIG. 4 is a graph showing the effect of pretreatment with inhaled D-propranolol (10 mg in 4 mL of PBS) on antigen-induced airway hyperresponsiveness. Data are shown as mean ± SE PD400 of carbachol in breath units (Cumulative provocating dose of carbachol, which increased SRL to 400% above the baseline). One breath unit is defined as one breath of 1% carbachol solution (P═NS).
- FIG. 5 is a graph showing the individual response of each sheep to the effect of pretreatment with inhaled D-propranolol on antigen-induced changes in PD400.
- FIG. 6 is a graph showing the SRL response of acute responder sheep to different dosages of inhaled D-propranolol. The response at the 10 mg/kg dose is significantly different from the control.
- FIG. 7 is a graph showing the PD400 response of acute responder sheep to different dosages of inhaled D-propranolol. The post antigen and 5 mg dose responses are significantly different from the baseline response, and the 20 mg dose response is significantly different from the post antigen response.
- FIG. 8 is a graph showing the SRL response of acute responder sheep to a 10 mg dose of inhaled L-propranolol. There is no significant difference from the control response.
- FIG. 9 is a graph showing the PD400 response of acute responder sheep to a 10 mg dose of inhaled L-propranolol.
- FIG. 10 is a graph showing the SRL response of acute responder sheep to a 5 mg/kg dose of oral D-propranolol.
- FIG. 11 is a graph showing the PD400 response of acute responder sheep to a 5 mg/kg dose of oral D-propranolol.
- FIG. 12 is a chart showing the timeline of the SRL response of dual responder sheep to a 5 mg/kg dose of inhaled D-propranolol.
- FIG. 13 is a graph showing the PD400 response of dual responder sheep to a 5 mg/kg dose of inhaled D-propranolol.
- FIG. 14 is a chart showing the timeline of the SRL response of dual responder sheep to a 10 mg/kg dose of inhaled D-propranolol.
- FIG. 15 is a graph showing the PD400 response of dual responder sheep to a 10 mg/kg dose of inhaled D-propranolol.
- FIG. 16 is a chart showing the timeline of the SRL response of dual responder sheep to a 5 mg/kg dose of oral D-propranolol.
- FIG. 17 is a graph showing the PD400 response of dual responder sheep to a 5 mg/kg dose of oral D-propranolol.
- FIG. 18 is a chart showing the timeline of the SRL response of dual responder sheep to a 10 mg/kg dose of inhaled L-propranolol.
- FIG. 19 is a graph showing the PD400 response of dual responder sheep to a 10 mg/kg dose of inhaled L-propranolol.
- The present invention includes compositions and methods for the treatment of asthma and related pathologies. The present invention also includes compounds that may have antioxidant activity and in some cases, lack ability to block beta receptors in the human or animal. The present invention comprises methods of treating asthma in a human or animal comprising the steps of administering to the human or animal with the asthma a composition comprising an effective amount of an antioxidant compound.
- One embodiment of the present invention is the use of D-propranolol or the congeners of D-propranolol as disclosed herein to inhibit asthma and related pathologies. The optical isomer of D-propranolol is L-propranolol. L-propranolol is in the class of drugs that cause beta receptor blockade. β-adrenergic blocking agents have been used to treat such diverse diseases as glaucoma, migraine. hypertension, myocardial infarct and tremor. For example, L-propranolol is administered orally and is metabolically converted in the body by hepatic p450 enzymes to a metabolite that is effective for blocking beta receptors found in bodily tissues such as the heart and lung, in addition to other organs. Thus, L-propranolol is used to treat high blood pressure and certain forms of angina.
- L-propranolol's sympathetic agonist or beta-blocker activity makes it an effective therapeutic for cardiac and hypertensive conditions, but this same activity creates adverse reactions for asthmatics. L-propranolol can precipitate asthma and in patients with severe asthma, the use of L-propranolol is contraindicated because serious or lethal asthmatic episodes of bronchoconstriction can occur.
- The optical isomer of L-propranolol, D-propranolol, is thought to be biologically inactive. Thus, it is the surprising finding of the compositions and methods of the present invention that D-propranolol is effective therapy for asthma. D-propranolol is effective in the prevention of antigen-induced bronchoconstriction in sheep. The sheep model is a good animal model for the asthmatic condition in humans.
- Though not wishing to be bound by any theory, it is theorized that D-propranolol, its metabolites and congeners and analogs play a role in stopping or inhibiting the inflammatory reactions mediated by mast cells and other inflammatory agents in asthma. Control of inflammatory reactions by D-propranolol, its metabolites and congeners and analogs make such compounds useful for treatment of other pathologies with inflammatory components. Diseases associated with chronic inflammation can be treated by the compositions and methods of the present invention. Diseases with symptoms of chronic inflammation include, but are not limited to, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, psoriasis, sarcoidosis and rheumatoid arthritis.
- Again, though not wishing to be bound by any particular theory, it is theorized that the antioxidant activities of the compositions of the present invention aid in the compositions' effectiveness in treatment of asthma. An antioxidant is more readily oxidized than is a second substance and therefore, the antioxidant retards or inhibits the oxidation of the second substance. Treatment of other disease states in which control of oxidative activity is relevant is contemplated by the methods and compositions of the present invention.
- The compounds and methods of the present invention may be used in treatment of cystic fibrosis. Cystic fibrosis is a genetic disease in which there is, among other pathologies, an overproduction of a thickened mucous and lack of digestive enzymes. Neutrophil elastase, released during an inflammatory response, is thought to play a central role in cystic fibrosis and in inflammatory disorders.
- Neutrophil elastase is a serine protease that is stored in granules of mature neutrophils and functions in degradation of phagocytosed proteins. During neutrophil stimulation, neutrophil elastase and other enzymes gain access to the extracellular space where they cause substantial damage to the surrounding lung tissue, inhibit cell functions and inactivate molecules relevant to the integrity of the lung.
- The lung is protected from neutrophil elastase and other such enzymes by several antiproteinases such as α1-proteinase inhibitor (α1-PI) and secretory leucoprotease inhibitor (SLPI). In a noninflamed lung, the activity of these antiproteinases functions to control proteinase activity and prevents proteinase damage to the lung. During neutrophil stimulation in an inflamed lung, in addition to proteinase release, stimulated neutrophils release reactive oxygen metabolites and the oxidative enzyme, myeloperoxidase. Not only are the reactive oxygen metabolites damaging to lung tissue, the protective antiproteinases are turned off by oxidative inactivation. Thus, compounds having antioxidative activity, such as those of the present invention, could function both in lung tissue protection and in preventing the inactivation of the protective enzymes.
- There are numerous veterinary applications for the compositions and methods of the present invention. For example, the compounds included in the present invention can be used to treat asthmatic animals such as race horses. Additionally, animals also suffer with diseases due to inflammatory and oxidative reactions.
- Compounds that can be used in accordance with the present invention include compounds that lack beta blocker activity. Additionally, compounds that can be used in accordance with the present invention include compounds that are capable of being acted on by the class of enzymes identified as p450 enzymes.
-
- In summary, a preferred compound is D-propranolol as well as congeners, analogs, hydrolysis products, metabolites and precursors of D-propranolol and may lack beta receptor blocking capabilities. Such compounds may also have antioxidative activity. Other preferred compounds are the appropriate enantimers or racemic mixture of bisoprolol, metoprolol, and carvedilol. It is envisioned that fluorinated congeners of all of these compounds are also useful for the present invention. However, it is to be understood that it is not necessary for a compound to have both a lack of beta receptor blocking activity and antioxidative activity to be considered part of the present invention. Such compounds as those acted upon by p450 enzymes are also contemplated by the present invention. It is to be understood that the compounds of the present invention can exist as enantiomers and that the racemic mixture of enantiomers or the isolated enantiomers are all considered as within the scope of the present invention.
- The compounds described above can be provided as pharmaceutically acceptable formulations using formulation methods known to those of ordinary skill in the art. These formulations can be administered by standard routes. In general, the combinations may be administered by the topical, transdermal, oral, nasal, rectal or parenteral (e.g., intravenous, subcutaneous or intramuscular) route. In addition, the combinations may be incorporated into biodegradable polymers allowing for sustained release of the compound.
- For inhalation formulations, the compounds of the present invention may be delivered via any inhalation methods known to those skilled in the art. Such inhalation methods and devices include, but are not limited to, metered dose inhalers with propellants such as CFC or HFA or propellants that are physiologically and environmentally acceptable. Other included devices are breath operated inhalers, multidose dry powder inhalers and aerosol nebulizers.
- The dosage of the compound will depend on the condition being treated, the particular compound, and other clinical factors such as weight and condition of the human or animal and the route of administration of the compound. It is to be understood that the present invention has application for both human and veterinary use.
- The formulations include those suitable for oral, inhalation, rectal, ophthalmic, (including intravitreal or intracameral) nasal, topical (including buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intratracheal, and epidural) administration. The formulations may conveniently be presented in unit dosage form and may be prepared by conventional pharmaceutical techniques. Such techniques include the step of bringing into association the active ingredient and the pharmaceutical carrier(s) or excipient(s). In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.
- Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil emulsion and as a bolus, etc.
- A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing, in a suitable machine, the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, preservative, surface active or dispersing agent. Molded tablets may be made by molding, in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent. The tablets may be optionally coated or scored and may be formulated so as to provide a slow or controlled release of the active ingredient therein.
- Formulation suitable for administration by inhalation includes formulations of the active ingredient in a form that can be dispensed by such inhalation devices known to those in the art. Such formulations may includes carriers such as powders and aerosols. The inhalant compositions used in the present invention may comprise liquid or powdered compositions containing the active ingredient that are suitable for nebulization and intrabronchial use, or aerosol compositions administered via an aerosol unit dispensing metered doses.
- Suitable liquid compositions comprise the active ingredient in an aqueous, pharmaceutically acceptable inhalant solvent, e.g., isotonic saline or bacteriostatic water. The solutions are administered by means of a pump or squeeze-actuated nebulized spray dispenser, or by any other conventional means for causing or enabling the requisite dosage amount of the liquid composition to be inhaled into the patient's lungs.
- Suitable powder compositions include, by way of illustration, powdered preparations of the active ingredient thoroughly intermixed with lactose or other inert powders acceptable for intrabronchial administration. The powder compositions can be administered via an aerosol dispenser or encased in a breakable capsule which may be inserted by the patient into a device that punctures the capsule and blows the powder out in a steady stream suitable for inhalation.
- Aerosol formulations for use in the subject method would typically include propellants, surfactants and co-solvents and may be filled into conventional aerosol containers that are closed by a suitable metering valve.
- Formulations suitable for topical administration in the mouth include lozenges comprising the ingredients in a flavored basis, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert basis such as gelatin and glycerin, or sucrose and acacia; and mouthwashes comprising the ingredient to be administered in a suitable liquid carrier.
- Formulations suitable for topical administration to the skin may be presented as ointments, creams, gels and pastes comprising the ingredient to be administered in a pharmaceutical acceptable carrier. A preferred topical delivery system is a transdermal patch containing the ingredient to be administered.
- Formulations for rectal administration may be prepared as a suppository with a suitable base comprising, for example, cocoa butter or a salicylate.
- Formulations suitable for nasal administration, wherein the carrier is a solid, include a coarse powder having a particle size, for example, in the range of 20 to 500 microns which is administered in the manner in which snuff is administered, i.e., by rapid inhalation through the nasal passage from a container of the powder held close up to the nose. Suitable formulations, wherein the carrier is a liquid, for administration, as for example, a nasal spray or as nasal drops, include aqueous or oily solutions of the active ingredient.
- Formulations suitable for vaginal administration may be presented as pessaries, tamports, creams, gels, pastes, foams or spray formulations containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
- Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain antioxidants, stabilizers, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) conditions requiring only the addition of the sterile liquid carrier, for example, water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
- Preferred unit dosage formulations are those containing a daily dose or unit, daily sub-dose, as herein above recited, or an appropriate fraction thereof, of the administered ingredient.
- It should be understood that in addition to the ingredients, particularly mentioned above, the formulations of the present invention may include other agents conventional in the art having regard to the type of formulation in question, for example, those suitable for oral administration may include flavoring agents.
- This invention is further illustrated by the following examples, which are not to be construed in any way as imposing limitations upon the scope thereof. On the contrary, it is to be clearly understood that resort may be had to various other embodiments, modifications, and equivalents thereof which, after reading the description herein, may suggest themselves to those skilled in the art without departing from the spirit of the present invention and/or the scope of the appended claims.
- D-propranolol was administered via the inhalation route as an aerosol one hour before antigen challenge in acute responder sheep. There was significant inhibition of allergic bronchoconstriction by the administered D-propranolol.
- The following protocol is a well-known and art accepted animal model for measurement of antigen-induced asthmatic treatments.
- Five allergic sheep, with previously documented acute bronchoconstrictor response toAscaris suum antigen, were used for all studies. The sheep were intubated with a cuffed nasotracheal tube and pulmonary airflow resistance (RL) was measured by the esophageal balloon catheter technique, while thoracic gas volume was measured by body plethysmography. Data was expressed as specific resistance, SRL. SRL is defined as RL times thoracic gas volume (Vtg).
- To assess the normal or baseline airway responsiveness of the sheep, cumulative dose response curves to inhaled carbochol were performed. The SRL of each sheep was measured before and after inhalation of a buffered saline solution and after each administration of 10 breaths of increasing concentrations of carbachol (0.25, 0.5, 1.0, 2.0 and 4.0% wt/vol solution). Airway responsiveness was defined by determination of the cumulative provocation dose (PD400) of carbachol (in breath units) that increased SRL to 400% above baseline. One breath unit was defined as one breath of 1% carbachol solution.
- FIG. 1 shows the effect of treatment using D-propranolol in an antigen challenge experiment. The normal reaction of the sheep to the antigen fromAscaris suum is measured. After full recovery and a two week rest period, the sheep again undergo repeat antigen challenge, but this time only after treatment with D-propranolol.
- The SRL of the acute responder sheep was measured prior to any treatment (baseline). The normal response of the sheep to antigen challenge by Ascaris suum antigen was measured (Open circles). After appropriate recovery of at least two weeks, D-propranolol, 10 mg in 4 mL of PBS, (phosphate buffered saline), was administered as an aerosol one hour before antigen challenge in acute responder sheep and the SRL was measured (PD). One hour after D-propranolol was administered, the sheep were challenged with Ascaris suum antigen by inhalation. The SRL was measured immediately after antigen challenge (AG0). As can be seen in FIG. 1, the sheep treated with D-propranolol (black circles) showed significantly less immediate allergic bronchoconstriction response to antigen challenge compared to the control, non-treated, sheep (open circles).
- FIG. 2 shows the percentage change in SRL for control conditions (normal response to Ascaris suum antigen) and treatment conditions (D-propranolol). When the sheep were treated with D-propranolol there was significantly less change in SRL after antigen stimulation than under the control conditions.
- FIG. 3 shows the individual responses for the five sheep. As the graph shows, there was variability in the responses of the five sheep, but all sheep showed a difference in response to antigen after treatment with D-propranolol.
- FIG. 4 shows that treatment with D-propranolol maintains the sheep's airway responsiveness to antigen at or near baseline responsiveness levels. The effect of antigen on the sheep was to make the airway more responsive, thus lowering the PD400 value. Treatment with D-propranolol maintained the airway responsiveness levels at the baseline or normal responsiveness levels of the sheep.
- FIG. 5 shows the individual airway responsiveness of each sheep to the treatment with D-propranolol. When challenged by antigen, each sheep showed a decreased PD400. The effect of treatment with D-propranolol on airway responsiveness was different for each sheep.
- As can be seen from these experiments, treatment with D-propranolol can attenuate an antigen-induced asthma attack.
- The comparative effects of L- and D-propranolol on antigen-induced bronchorestriction (ABR) and airway hyperresponsiveness (AHR) in sheep were tested. The sheep were treated as described in Example I. Propranolol, a nonselective beta-receptor antagonist is known to cause bronchorestrictions and worsen AHR.
- Specific lung resistance (SRL) was measured in 11 allergic sheep, of which six sheep were acute responders and five sheep were dual responders, before and serially after challenge with Ascaris suum antigen, without and after pretreatment with D- or L-propranolol. The propranolol was administered either in an inhaled dose or an oral dose.
- The following experiments used inhaled D- or L-propranolol. AHR was estimated at 2 hours (acute) or 24 hours (dual) after antigen challenge as the provocating dose of carbachol which increased SRL by 400% (PD400). In acute responders, SRL increased by 219% with antigen challenge and PD400 decreased by 55%. Inhaled D-propranolol had no effect on baseline SRL, but inhibited ABR in a dose dependent manner. As shown in FIG. 6, ABR was inhibited by 37% at a 5 mg dose, by 68% at a 10 mg dose and 44% at a 20 mg dose. The 68% inhibition is significant, P<0.05. As shown in FIG. 7, AHR was inhibited by 30 % at a 5 mg dose, 50% at a 10 mg dose, and 75% at a 20 mg dose. The 75% inhibition is significant, P<0.05, when compared to the post-antigen response. The 5 mg dose response is significantly different from the baseline response.
- FIG. 8 shows that inhaled L-propranolol (10 mg dose) increased baseline SRL, which resolved by 30 minutes, but had no effect on ABR, where the change in SRL=209%. FIG. 9 shows the AHR response to inhaled L-propranolol where there is no difference between the post antigen and L-propranolol responses, though both are statistically different from the baseline response.
- Oral administration of D-propranolol also effects ABR and AHR responses. FIG. 10 shows the change in SRL to a 5 mg/kg dose of oral D-propranolol in acute responder sheep and FIG. 11 shows the change in PD400 after oral administration of 5 mg/kg of D-propranolol.
- In dual responders, L-propranolol was ineffective, with peak early change in SRL=351%, peak late SRL=175%, as shown in FIG. 18, and had no effect on PD400 as shown in FIG. 19. With D-propranolol, at a 5 mg dose, partly attenuated the early phase and late phase by 35% and 21%, respectively, and inhibited AHR by 44% (P<0.05), as shown in FIGS. 12 and 13. Inhaled D-propranolol at a 10 mg dose also effected ABR, see FIG. 14, and AHR, see FIG. 15.
- The route of administration was not critical in the effect of D-propranolol on ABR and AHR. As shown in FIG. 16, oral administration of 5 mg/kg of D-propranolol significantly effected the early phase of dual responder sheep, and may even remove the late phase response. A 5 mg/kg oral dose also effected AHR as shown in FIG. 17.
- It should be understood, of course, that the foregoing relates only to preferred embodiments of the present invention and that numerous modifications or alterations may be made therein without departing from the spirit and the scope of the invention as set forth in the appended claims.
Claims (7)
1. A method of treatment of bronchorestriction in a human or animal, comprising administering an effective amount of a drug selected from the group consisting of D-propranolol, metoprolol, carvedilol, and bisoprolol and congeners and analogs, and metabolites thereof, to inhibit bronchorestriction in the human or animal.
2. The method of claim 1 , wherein the bronchorestriction is asthma.
3. The method of claim 1 , wherein the bronchorestriction is bronchial hyperresponsiveness.
4. A composition for treating bronchorestriction, comprising
(a) a drug selected from the group consisting of D-propranolol, metoprolol, carvedilol, and bisoprolol and congeners and analogs, and metabolites thereof, admixed with
(b) a pharmaceutically acceptable carrier.
5. The composition of claim 4 , wherein the drug comprises D-propranolol.
6. A dosage unit comprising an amount of drug selected from the group consisting of D-propranolol, metoprolol, carvedilol, and bisoprolol and congeners and analogs, and metabolites thereof, admixed with a carrier effective to treat asthma.
7. A method of treatment of inflammation in a human or animal, comprising the administration of an effective amount of a drug selected from the group consisting of D-propranolol, metoprolol, carvedilol, and bisoprolol and congeners and analogs, and metabolites thereof, to inhibit inflammation in the human or animal.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/770,631 US20020013373A1 (en) | 1997-03-13 | 2001-01-29 | Methods and compositions for treatment of asthma |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4074597P | 1997-03-13 | 1997-03-13 | |
US09/042,344 US6284800B1 (en) | 1997-03-13 | 1998-03-13 | Methods and compositions for treatment of asthma |
US09/770,631 US20020013373A1 (en) | 1997-03-13 | 2001-01-29 | Methods and compositions for treatment of asthma |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/042,344 Division US6284800B1 (en) | 1997-03-13 | 1998-03-13 | Methods and compositions for treatment of asthma |
Publications (1)
Publication Number | Publication Date |
---|---|
US20020013373A1 true US20020013373A1 (en) | 2002-01-31 |
Family
ID=26717379
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/042,344 Expired - Fee Related US6284800B1 (en) | 1997-03-13 | 1998-03-13 | Methods and compositions for treatment of asthma |
US09/770,631 Abandoned US20020013373A1 (en) | 1997-03-13 | 2001-01-29 | Methods and compositions for treatment of asthma |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/042,344 Expired - Fee Related US6284800B1 (en) | 1997-03-13 | 1998-03-13 | Methods and compositions for treatment of asthma |
Country Status (1)
Country | Link |
---|---|
US (2) | US6284800B1 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6733789B1 (en) | 1999-01-21 | 2004-05-11 | Biovail Laboratories, Inc. | Multiparticulate bisoprolol formulation |
US20040185099A1 (en) * | 2000-01-20 | 2004-09-23 | Biovail Laboratories, Inc. | Multiparticulate bisoprolol formulation |
WO2002024198A1 (en) * | 2000-09-21 | 2002-03-28 | University Of Houston | Novel therapy |
AU2001294808A1 (en) * | 2000-09-29 | 2002-04-08 | Board Of Trustees Operating Michigan State University | Catecholamine pharmaceutical compositions and methods |
US20030118652A1 (en) * | 2001-11-15 | 2003-06-26 | John Kelly | Methods and compositions for use of (S)-bisoprolol |
US20030091633A1 (en) * | 2001-11-15 | 2003-05-15 | John Kelly | Methods and compositions for use of (S)-bisoprolol |
US20050143378A1 (en) * | 2003-12-29 | 2005-06-30 | Yun Anthony J. | Treatment of conditions through pharmacological modulation of the autonomic nervous system |
US20050153885A1 (en) * | 2003-10-08 | 2005-07-14 | Yun Anthony J. | Treatment of conditions through modulation of the autonomic nervous system |
US20070276024A1 (en) * | 2003-10-09 | 2007-11-29 | Inverseon , Inc. | Methods for Treating Diseases and Conditions with Inverse Agonists and for Screening for Agents Acting as Inverse Agonists |
CA2544611A1 (en) * | 2003-10-09 | 2005-04-21 | Inverseon, Inc. | Method of treating airway diseases with beta-adrenergic inverse agonists |
US7528175B2 (en) * | 2004-10-08 | 2009-05-05 | Inverseon, Inc. | Method of treating airway diseases with beta-adrenergic inverse agonists |
JP6527305B2 (en) | 2011-01-10 | 2019-06-05 | インヴィオン, インコーポレイテッド | Use of beta-adrenergic inverse agonists for smoking cessation |
-
1998
- 1998-03-13 US US09/042,344 patent/US6284800B1/en not_active Expired - Fee Related
-
2001
- 2001-01-29 US US09/770,631 patent/US20020013373A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US6284800B1 (en) | 2001-09-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11918655B2 (en) | Intranasal epinephrine formulations and methods for the treatment of disease | |
TWI758617B (en) | Aerosol pharmaceutical composition comprising glycopyrronium salt and indacaterol salt, its preparation method and use | |
US6284800B1 (en) | Methods and compositions for treatment of asthma | |
CH680983A5 (en) | ||
CA2327670A1 (en) | Pulmonary and nasal delivery of raloxifene | |
KR101312331B1 (en) | Nasal pharmaceutical formulations and methods of using the same | |
US5679714A (en) | Administration of ketamine for detoxification and treatment of tobacco addiction | |
CN110290809A (en) | Pharmaceutical dosage form comprising TASK-1 and TASK-3 channel inhibitor and its purposes for treating respiratory disorder | |
US20100292325A1 (en) | P-menthawe-3-carboxylic acid esters to treat airways diseases | |
CA2588042A1 (en) | Compositions and methods for pulmonary conditions | |
JPH07509476A (en) | Medications for the treatment or prevention of high intraocular pressure | |
KR20100021451A (en) | Methods and compositions for administration of oxybutynin | |
US4908382A (en) | Method for treating asthma | |
US8703158B2 (en) | Theobromine for the treatment of cough | |
JPH11500729A (en) | Nasal and ophthalmic administration of ketamine for pain management and detoxification | |
AU2024201523A1 (en) | Intranasal epinephrine formulations and methods for the treatment of disease | |
Johnson | Principles of nebulizer-delivered drug therapy for asthma | |
US4689213A (en) | Method and composition for treating bronchospastic airway diseases | |
WO2020019953A1 (en) | Aerosol pharmaceutical composition containing a glycopyrrolate salt, preparation method therefor, and uses thereof | |
TW201016215A (en) | Compositions and uses of antiviral active pharmaceutical agents | |
US9238019B2 (en) | Antitussive and bronchodilator uses for enaminone ester | |
Rogers | Combined inhalation of cromolyn sodium and metaproterenol sulfate in life-threatening asthma. | |
NO871058L (en) | PROCEDURE AND PREPARATION FOR TREATMENT OF BRONCHOSPASTIC RESPIRATORY DISEASES. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |